Re: Increasing Participation in Cervical Cancer Screening

Why It Matters

Increasing screening uptake through affordable self‑sampling can close the urban‑rural gap in China, while early HPV vaccination dramatically reduces cancer risk, offering a dual strategy for public‑health impact.

Key Takeaways

• Menstrual blood self-sampling showed 94.7% sensitivity for CIN2+ in China.
• National screening coverage reached 51.5% overall, but rural rates lag at 48.2%.
• Swedish study found 79% reduction in invasive cervical cancer after early vaccination.
• HPV vaccination in China began only in November 2025.
• WHO endorses vaginal self‑swabs as cost‑effective interim screening method.

Pulse Analysis

Cervical cancer remains a leading cause of mortality among women worldwide, and China’s massive population amplifies the public‑health stakes. Although national screening programs have expanded, the latest China CDC data reveal that rural participation hovers just below the 50% target, leaving millions of women without routine cytology or HPV testing. Self‑sampling—particularly non‑invasive approaches—offers a pragmatic solution to bridge geographic and socioeconomic barriers, aligning with global calls for equity‑focused cancer prevention.

The Tian et al. study introduced menstrual‑blood HPV testing via a minipad, reporting 94.7% sensitivity for CIN2+ lesions, comparable to clinician‑collected samples. However, the method’s specificity was marginally lower (89.1% vs 90.0%) and the capture‑sequencing platform remains unvalidated outside research settings. In contrast, vaginal self‑swabs are already WHO‑endorsed, have established supply chains, and demonstrate robust cost‑effectiveness in low‑resource environments. Policymakers should therefore adopt vaginal self‑swabs as the interim standard while commissioning rigorous health‑economic analyses of menstrual‑blood kits.

Vaccination data reinforce the urgency of a combined strategy. A nationwide Swedish register analysis of 926,362 women showed a 79% reduction in invasive cervical cancer among those vaccinated before age 17, with school‑based programs outperforming opportunistic delivery. China’s HPV vaccine rollout, launched only in November 2025, must learn from this evidence by prioritising school‑based administration and integrating vaccination records with screening registries. Together, expanded self‑sampling and early vaccination can accelerate progress toward the 2025 national screening target and ultimately lower cervical cancer incidence across urban and rural China.